A simple and reproducible prognostic index in luminal ER-positive breast cancers

作者：Castellano I^*; Chiusa L; Vandone A M; Beatrice S; Goia M; Donadio M; Arisio R; Muscara F; Durando A; Viale G; Cassoni P; Sapino A

来源：Annals of Oncology, 2013, 24(9): 2292-2297.

DOI：10.1093/annonc/mdt183

• AR expression
• breast cancer
• ER expression
• lymph nodal status
• prognostic index
• tumor size

Background: The group of estrogen receptor (ER)-positive breast cancers (both luminal-A and -B) behaves differently from the ER-negative group. At least in early follow-up, ER expression influences positively patients%26apos; prognosis. This low aggressive biology flattens out the differences of clinical management. Thus we aimed to produce a prognostic index specific for ER-positive (ERPI) cancers that could be of aid for clinical decision. %26lt;br%26gt;Patients and methods: The test set comprised 495 consecutive ER-positive breast cancers. Tumor size, number of metastatic lymph nodes and androgen receptor expression were the only independent variables related to disease-specific survival. These variables were used to create the ERPI, which was applied to the entire test set and to selected subpopulations (grade 2 (G2)-tumors, luminal-A and -B breast cancers). A series of 581 ER-positive breast cancers, collected from another hospital, was used to validate ERPI. %26lt;br%26gt;Results: In the test population, 96.9% of patients classified as ERPI-good showed a good prognosis compared with 79.6% classified as ERPI-poor (P %26lt; 0.001). ERPI effectively discriminated outcome in luminal-A and luminal-B and in G2-tumors. In the validation series, the ERPI maintained its value. %26lt;br%26gt;Conclusion: ERPI is a practical tool in refining the prediction of outcome of patients with ER-positive breast cancer.

• 出版日期2013-9